News
GSK’s anti-BCMA drug Blenrep wins US approval
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s anti-BCMA therapy Blenrep (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma.